Glycomimetics as selectin antagonists and pharmaceuticals having antiinflammatory activity prepared therefrom
    13.
    发明授权
    Glycomimetics as selectin antagonists and pharmaceuticals having antiinflammatory activity prepared therefrom 失效
    作为选择素拮抗剂的甘油模拟物和由其制备的具有抗炎活性的药物

    公开(公告)号:US06197752B1

    公开(公告)日:2001-03-06

    申请号:US08708475

    申请日:1996-09-05

    IPC分类号: A61K3170

    CPC分类号: C07D309/10 C07D307/20

    摘要: The invention relates to novel mimetics of the tetrasaccharides sialyl- Lewis-X (SLeX) and sialyl- Lewis-A (SLeA) having an improved action as inhibitors of cell adhesion, specifically a compound of the formula I in which R1 is —H, —CH3 or —CH2OH, R2 is —H or —OH, R3, R4 and R5 independently of one another are —H, C1-C4-alkyl or —OH, R6, R7, R8, R9 and R10 independently of one another are —H or C1-C4-alkyl D is —O—C(O)—, —C(O)—or —NR6—C(O)—, E is —CR7R8—, —NR7—, or a nitrogen heterocycle of the formula n is 1 or 2, m is 0 or 1, p is an integer from 0 to 10, q is 1 or 2 and X1 and X2 independently of one another are —H, —COOR9, —NR9R10, —OH, —OSO3H, —CH2COOR9 or —CH2OSO3H or together are ═O, to a process for preparing these compounds and to their use as pharmacological active compounds and diagnostic agents.

    摘要翻译: 本发明涉及具有作为细胞粘附抑制剂的改善作用的四糖唾液酸基-LX-X(SLeX)和唾液酸 - 路易斯-A(SLeA)的新型模拟物,特别是式Iin化合物,其中R 1为-H,-CH 3 或-CH 2 OH,R 2是-H或-OH,R 3,R 4和R 5彼此独立地是-H,C 1 -C 4 - 烷基或-OH,R 6,R 7,R 8,R 9和R 10彼此独立地是-H 或C 1 -C 4 - 烷基D为-OC(O) - , - C(O) - 或-NR 6 -C(O) - ,E为-CR 7 R 8 - , - NR 7 - 或式 2,m为0或1,p为0至10的整数,q为1或2,X 1和X 2彼此独立地为-H,-COOR 9,-NR 9 R 10,-OH,-OSO 3 H,-CH 2 COOR 9或-CH 2 OSO 3 H 或一起是= O,涉及制备这些化合物的方法及其作为药理活性化合物和诊断剂的用途。

    PROCESS FOR THE PRODUCTION OF BENZOFURANS
    14.
    发明申请
    PROCESS FOR THE PRODUCTION OF BENZOFURANS 有权
    生产苯甲醚的方法

    公开(公告)号:US20120065411A1

    公开(公告)日:2012-03-15

    申请号:US13321754

    申请日:2010-05-26

    CPC分类号: C07D307/80 C07C205/45

    摘要: A process for the production of 2-alkyl-3-aroyl-5-nitrobenzofurans by acylation of 2-(2-hydroxy-5-nitrophenyl)-1-aryl-ethanones and subsequent treatment of the esters with combinations of bases and proton acids or Lewis acids. This process can be used for the production of Dronedarone. Furthermore, novel intermediates for the manufacture of Dronedarone are provided.

    摘要翻译: 通过2-(2-羟基-5-硝基苯基)-1-芳基乙酰胺的酰化生产2-烷基-3-芳酰基-5-硝基苯并呋喃的方法,随后用碱和质子酸的组合处理酯 或路易斯酸。 该方法可用于生产决奈达隆。 此外,还提供了制备决奈达隆的新型中间体。

    PROCESS FOR THE PRODUCTION OF DRONEDARONE INTERMEDIATES
    16.
    发明申请
    PROCESS FOR THE PRODUCTION OF DRONEDARONE INTERMEDIATES 有权
    生产干粉碎石中间体的方法

    公开(公告)号:US20120077995A1

    公开(公告)日:2012-03-29

    申请号:US13322094

    申请日:2010-05-26

    IPC分类号: C07D307/80

    CPC分类号: C07D307/80

    摘要: A process for the production of Dronedarone intermediates of the formula (I), by acylation of 2-(2-hydroxy-5-nitrophenyl)-1-(4-methoxyphenyl)-ethanone, subsequent treatment of the ester with bases and a zeolite (alumosilicate) catalyst and optional subsequent demethylation. This process can be used for the production of Dronedarone.

    摘要翻译: 通过2-(2-羟基-5-硝基苯基)-1-(4-甲氧基苯基) - 乙酮的酰化生产式(I)的决奈达隆中间体的方法,随后用碱和沸石处理酯 (铝硅酸盐)催化剂和随后的脱甲基化。 该方法可用于生产决奈达隆。

    Antiinflammatory cell adhesion inhibitors
    18.
    发明授权
    Antiinflammatory cell adhesion inhibitors 失效
    抗炎细胞粘附抑制剂

    公开(公告)号:US6110897A

    公开(公告)日:2000-08-29

    申请号:US948294

    申请日:1997-10-10

    IPC分类号: C07H7/027 A61K31/70 C07H15/00

    CPC分类号: C07H7/027

    摘要: The invention relates to compounds of formula Ix and Ia: ##STR1## wherein (Ix) comprises the regioisomeric form sLe.sup.X and (Ia) comprises the regioisomeric form sLe.sup.A, and R.sup.1 is a lipophilic radical formed from aliphatic or cycloaliphatic units, or a sugar residue which is capped by a .beta.1-O-linked aliphatic or cycloaliphatic unit at the reducing end of the terminal sugar. The compounds of the present invention are useful as inhibitors of increased cell-cell adhesion as well as useful in treating diseases associated with increased cell-cell-adhesion. The compounds of the present invention are also incorporated into pharmaceutical compositions.

    摘要翻译: 本发明涉及式Ix和Ia的化合物:其中(Ix)包含区域异构形式的sLeX,(Ia)包含区域异构形式的sLeA,并且R 1是由脂族或脂环族单元形成的亲脂基团,或被封端的糖残基 通过在末端糖的还原端的β1-O-连接的脂族或脂环族单元。 本发明的化合物可用作增加的细胞 - 细胞粘附的抑制剂,并且可用于治疗与增加的细胞 - 细胞粘附相关的疾病。 本发明的化合物也并入药物组合物中。